Headaches & Migraines

US Food and Drug Administration Approves New Pneumococcal Vaccine

July 17, 2024 · 1 min read

Merck & Co.’s new vaccine, CAPVAXIVE (V116), has been approved by the FDA for preventing invasive diseases and pneumonia in adults 18 and older caused by specific strains of the bacteria Streptococcus pneumoniae. This vaccine is particularly aimed at protecting adults over 50 from around 84% of invasive pneumococcal diseases. In several studies, CAPVAXIVE showed strong immune responses in both people new to vaccines and those who had previous vaccinations. 

JoinAStudy.ca would like to congratulate Dr Peter Dzongowski and his team at Milestone Research, whose efforts were crucial in gathering the data necessary to arrive at these conclusions and eventual approval. The study participants also deserve acknowledgment and thanks for providing their valuable time and effort.   

The vaccine was developed to cover more strains of pneumococcal diseases than other vaccines already available, including eight unique serotypes that are responsible for a significant percentage of cases in older adults. Clinical trials demonstrated that CAPVAXIVE effectively triggers immune responses and has a safety profile similar to other vaccines. The CDC’s Advisory Committee on Immunization Practices will soon provide recommendations on using CAPVAXIVE in adults. 

Key safety information includes not administering the vaccine to individuals with severe allergies to its components and acknowledging that immunocompromised individuals may have a reduced response. Common side effects include pain at the injection site, fatigue, and headaches. 

To read the full press release from Merck & Co., please click here. 

This article is general health information, not medical advice. Talk to your own doctor about your situation.
The Canadian Health Newsletter

Get Headaches & Migraines research updates by email

One email a month: new studies and plain-language articles from our health library.

Study alerts: an email only when a matching study opens. Community: our research team may contact you about studies that may fit. Join the community

Ready when you are

See which studies you may qualify for

About five minutes. Free, and no obligation to take part.